Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 1:04 AM
Ignite Modification Date:
2025-12-25 @ 1:04 AM
NCT ID:
NCT02232893
Eligibility Criteria:
Inclusion Criteria:
* Be at least 18 years of age
* Has a current diagnosis of colon cancer, diverticulitis, or benign colonic neoplasm
* Requires straight, hand-assisted, or robot-assisted laparoscopic colectomy
* Requires hospitalization for surgery and recovery
Exclusion Criteria:
* Has been diagnosed with rectal cancer, advanced or metastatic colon cancer, Crohn disease, ulcerative colitis, or volvulus
* Requires resection of rectal lesion
* Has received or is scheduled to receive chemotherapy during the duration of the study
* Is a pregnant or lactating female
* Has diabetic neuropathy
* Has a history or presence of diabetic gastroparesis
* Has a compromised immune system, either from treatment with corticosteroids or other immunosuppressive agent within 2 weeks of surgery or from immunosuppressive disease (e.g., human immunodeficiency virus)
* Has any other serious condition that might adversely affect suitability for participation in this study, such as liver disorder (including alanine aminotransferase or aspartate aminotransferase level greater than 2.5 times the upper limit of normal), kidney disorders, heart failure, blood disorders, or metabolic disorders
* Has a history or presence of interstitial pneumonia
* Has a history of allergic reaction to ginseng, ginger or Zanthoxylum fruit (Japanese pepper)
* Plans to receive any abdominal irradiation
* Is clinically lactose intolerant
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT02232893
Study Brief:
Protocol Section:
NCT02232893